{"id":363833,"date":"2025-08-31T11:01:00","date_gmt":"2025-08-31T11:01:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-enliven-therapeutics\/"},"modified":"2025-08-31T11:01:00","modified_gmt":"2025-08-31T11:01:00","slug":"how-to-buy-enliven-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","title":{"rendered":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-363833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Enliven Therapeutics (ELVN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin, 2025 performans\u0131n\u0131 analiz edin ve bu klinik a\u015famadaki biyoteknoloji \u015firketindeki yat\u0131r\u0131m riskleri ve f\u0131rsatlar\u0131n\u0131 anlay\u0131n.","description_source":{"label":"Description","type":"textarea","formatted_value":"Enliven Therapeutics (ELVN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin, 2025 performans\u0131n\u0131 analiz edin ve bu klinik a\u015famadaki biyoteknoloji \u015firketindeki yat\u0131r\u0131m riskleri ve f\u0131rsatlar\u0131n\u0131 anlay\u0131n."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Enliven Therapeutics, keskin bilim ile hayat de\u011fi\u015ftiren hasta sonu\u00e7lar\u0131n\u0131n bulu\u015ftu\u011fu hassas onkolojinin heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki biyoteknoloji \u015firketi, kronik miyeloid l\u00f6semi tedavisinde devrim yaratabilir ve ileri g\u00f6r\u00fc\u015fl\u00fc yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir f\u0131rsat sunar.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Enliven Therapeutics, keskin bilim ile hayat de\u011fi\u015ftiren hasta sonu\u00e7lar\u0131n\u0131n bulu\u015ftu\u011fu hassas onkolojinin heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki biyoteknoloji \u015firketi, kronik miyeloid l\u00f6semi tedavisinde devrim yaratabilir ve ileri g\u00f6r\u00fc\u015fl\u00fc yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir f\u0131rsat sunar."},"body_html":"<h2>\ud83d\udcc8 Enliven Therapeutics Hisse Analizi: Mevcut Durum ve Gelecek Potansiyeli<\/h2> <p><strong>31 A\u011fustos 2025 itibar\u0131yla, Enliven Therapeutics (ELVN) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na 20,68 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>. Hisse senedi 2025 boyunca \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve 52 haftal\u0131k aral\u0131kta 13,30 $ ile 30,03 $ aras\u0131nda i\u015flem g\u00f6rerek yat\u0131r\u0131mc\u0131lar i\u00e7in hem \u00f6nemli risk hem de f\u0131rsat sundu.<\/p> <p>Takviminize not edin: <strong>12 Kas\u0131m 2025<\/strong>, ELVN yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 bu tarih, ge\u00e7mi\u015fte b\u00fcy\u00fck fiyat hareketlerini tetikleyebilir.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>\u00d6nemli olaylar etraf\u0131ndaki son performansa bakmak de\u011ferli i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p> <p><strong>13 A\u011fustos 2025<\/strong> - 2. \u00c7eyrek Kazan\u00e7 Raporu: ELVN, piyasa beklentilerinin \u00fczerinde, EPS -0,49 $ ile -0,53 $ olan konsens\u00fcs tahminini a\u015ft\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/ELVN\/earnings\/\">MarketBeat Kazan\u00e7 Verileri<\/a>). Bu olumlu s\u00fcrpriz, \u015firketin giderleri y\u00f6netme ve klinik programlar\u0131 ilerletme yetene\u011fini g\u00f6sterdi.<\/p> <p>Hissenin bu habere tepkisi \u00f6zellikle dikkat \u00e7ekiciydi\u2014bir\u00e7ok biyoteknoloji \u015firketi kazan\u00e7 g\u00fcnlerinde dramatik dalgalanmalar ya\u015farken, ELVN nispeten istikrar g\u00f6sterdi; bu da uzun vadeli geli\u015fim s\u00fcrecini anlayan olgun bir yat\u0131r\u0131mc\u0131 taban\u0131n\u0131 i\u015faret ediyor.<\/p> <h3>Alt\u0131 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h3> <p>ELVN, son alt\u0131 ayda zorlu ama umut verici bir yol izledi:<\/p> <table> <thead> <tr><th>Ay<\/th><th>\u00d6nemli Olaylar<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>Trend<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>Erken klinik veri iyimserli\u011fi<\/td><td>25-28 $<\/td><td>\u2197\ufe0f Yukar\u0131 y\u00f6nl\u00fc momentum<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc bask\u0131s\u0131<\/td><td>18-22 $<\/td><td>\u2198\ufe0f Sekt\u00f6r genelinde d\u00fczeltme<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>Konferans sunumu haz\u0131rl\u0131klar\u0131<\/td><td>20-24 $<\/td><td>\u27a1\ufe0f Konsolidasyon<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>EHA Kongresi veri a\u00e7\u0131klamas\u0131<\/td><td>22-27 $<\/td><td>\u2197\ufe0f G\u00fc\u00e7l\u00fc olumlu tepki<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>Konferans sonras\u0131 kar realizasyonu<\/td><td>19-23 $<\/td><td>\u2198\ufe0f Sa\u011fl\u0131kl\u0131 geri \u00e7ekilme<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>2. \u00e7eyrek kazan\u00e7lar\u0131 ve kilitlenme s\u00fcresi biti\u015fi<\/td><td>20-21 $<\/td><td>\u27a1\ufe0f Olaylar aras\u0131nda istikrar<\/td><\/tr> <\/tbody> <\/table> <p><strong>Avrupa Hematoloji Derne\u011fi kongresinde ELVN-001 verilerinin ard\u0131ndan %11 hisse art\u0131\u015f\u0131<\/strong> (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Oncology Pipeline Raporu<\/a>), klinik d\u00f6n\u00fcm noktalar\u0131n\u0131n bu sekt\u00f6rde de\u011ferlemeyi nas\u0131l etkiledi\u011fini g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, yat\u0131r\u0131mc\u0131lar\u0131n bekleyebilece\u011fi \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi: 25-30 $<\/strong> - Devam eden denemelerden gelen olumlu veriler, ELVN'yi son i\u015flem aral\u0131\u011f\u0131n\u0131n \u00fcst s\u0131n\u0131r\u0131na do\u011fru itebilir. Kas\u0131m kazan\u00e7lar\u0131 y\u0131l sonu ivmesini belirlemede kritik olacak.<\/p> <p><strong>2026 Tahmini: 35-45 $<\/strong> - Faz 2 denemeleri ba\u015far\u0131l\u0131 ba\u015flarsa ve d\u00fczenleyici yollar temizlenirse, ELVN klinik riskin azalmas\u0131yla \u00f6nemli bir yeniden de\u011ferleme g\u00f6rebilir.<\/p> <p><strong>2028 Projeksiyonu: 50-70 $<\/strong> - Potansiyel d\u00fczenleyici ba\u015fvurular ve ortakl\u0131k g\u00f6r\u00fc\u015fmeleri, de\u011ferlemeyi analist fiyat hedefleri olan 50 $+ aral\u0131\u011f\u0131na ta\u015f\u0131yabilir.<\/p> <p><strong>2030 Vizyonu: 80-100 $+<\/strong> - Ba\u015far\u0131l\u0131 ticarile\u015fme ve pazar penetrasyonu, ELVN'yi milyarlarca dolarl\u0131k bir \u015firket haline getirebilir; ancak bu tamamen klinik ba\u015far\u0131 ve d\u00fczenleyici onaya ba\u011fl\u0131d\u0131r.<\/p> <p><strong>Karar: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong> - 3-5 y\u0131ll\u0131k bir perspektifle. Ortalama 41,20 $ fiyat hedefi olan analist konsens\u00fcs\u00fc (<a href=\"https:\/\/stockanalysis.com\/stocks\/elvn\/forecast\/\">Stock Analysis<\/a>) mevcut seviyelerden %100'\u00fcn \u00fczerinde potansiyel y\u00fckseli\u015f anlam\u0131na geliyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong> - Biyoteknoloji hisselerinin yakla\u015f\u0131k %60'\u0131 olumsuz deneme sonu\u00e7lar\u0131nda %50'den fazla de\u011fer kayb\u0131 ya\u015far. ELVN'nin t\u00fcm de\u011ferlemesi ELVN-001'in ba\u015far\u0131s\u0131na ba\u011fl\u0131d\u0131r.<\/li> <li><strong>D\u00fczenleyici Gecikmeler<\/strong> - FDA inceleme s\u00fcre\u00e7leri beklenmedik \u015fekilde 6-12 ay uzayabilir, potansiyel kazan\u00e7lar\u0131 dondurur ve belirsizlik yarat\u0131r.<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong> - Yak\u0131n zamanda 200 milyon $ sermaye art\u0131r\u0131m\u0131 yap\u0131lmas\u0131na ra\u011fmen (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Sermaye Art\u0131r\u0131m\u0131 Detaylar\u0131<\/a>), \u015firketin -52,7 milyon $ negatif nakit ak\u0131\u015f\u0131 dikkatle izlenmelidir.<\/li> <li><strong>Y\u00fcksek Volatilite<\/strong> - G\u00fcnl\u00fck ortalama %4,37 dalgalanma ve %95 kurumsal sahiplik ile b\u00fcy\u00fck i\u015flemler hisse fiyat\u0131n\u0131 dramatik \u015fekilde etkileyebilir.<\/li> <\/ul> <h3>2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>\u00c7\u0131\u011f\u0131r A\u00e7an Klinik Veriler<\/strong> - ELVN-001, yo\u011fun tedavi g\u00f6rm\u00fc\u015f CML hastalar\u0131nda %47 MMR oranlar\u0131 g\u00f6stererek, Scemblix gibi yerle\u015fik tedavilere kar\u015f\u0131 rekabet\u00e7i konumda.<\/li> <li><strong>Ba\u015far\u0131l\u0131 Fonlama<\/strong> - 200 milyon $ sermaye art\u0131r\u0131m\u0131, 2029'a kadar finansal destek sa\u011flayarak k\u0131sa vadeli seyrelme endi\u015felerini azalt\u0131yor.<\/li> <li><strong>Analist G\u00fcveni<\/strong> - T\u00fcm 5 analist \"G\u00fc\u00e7l\u00fc Al\" notunu koruyor ve fiyat hedefleri 52 $'a kadar \u00e7\u0131k\u0131yor.<\/li> <li><strong>Pazar \u0130htiyac\u0131<\/strong> - CML, tedaviye diren\u00e7li hastalarda \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7lar\u0131 olan 7 milyar $+ b\u00fcy\u00fckl\u00fc\u011f\u00fcnde bir pazar temsil ediyor.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ELVN gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n. Potansiyel \u00f6d\u00fcller b\u00fcy\u00fck, ancak riskler de \u00f6yle.<\/li> <li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong> - Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine, giri\u015f fiyat\u0131n\u0131z\u0131 ortalamak i\u00e7in birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck miktarlarda al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li> <li><strong>12 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong> - 3. \u00e7eyrek kazan\u00e7lar\u0131 i\u00e7in takviminize not edin ve bu olay etraf\u0131nda olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun.<\/li> <li><strong>Esprili t\u00fcccar bilgeli\u011fi<\/strong>: \"Biyoteknolojiye yat\u0131r\u0131m yapmak lise fl\u00f6rt\u00fc gibidir\u2014%90 drama, %10 ger\u00e7ek ilerleme, ama o %10 i\u015fe yarad\u0131\u011f\u0131nda hayat de\u011fi\u015ftirebilir!\"<\/li> <\/ol> <h2>\u2705 Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri i\u00e7in rekabet\u00e7i \u00fccretler sunan bir arac\u0131 kurum se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile ba\u015flaman\u0131z i\u00e7in yeterlidir<\/td><\/tr> <tr><td>3<\/td><td>\"ELVN\" Aramas\u0131 Yap\u0131n<\/td><td>\u015eirket ad\u0131n\u0131 de\u011fil, tam borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve varsa komisyon maliyetlerini anlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Enliven Therapeutics gibi \u015firketlerle yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, piyasaya giri\u015fin daha eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Bu inan\u0131lmaz d\u00fc\u015f\u00fck giri\u015f engeli, yat\u0131r\u0131mc\u0131lar\u0131n stratejileri test etmelerine ve \u00f6nemli finansal taahh\u00fct olmadan deneyim kazanmalar\u0131na olanak tan\u0131r.<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama S\u00fcreci<\/strong> - Tek bir kimlik belgesi kullan\u0131larak 1 dakikal\u0131k KYC (M\u00fc\u015fterini Tan\u0131) s\u00fcreci sayesinde, kaydolduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li> <li><strong>Geni\u015f \u00c7ekim Se\u00e7enekleri<\/strong> - Kripto paralar, e-c\u00fczdanlar ve geleneksel banka se\u00e7enekleri dahil 100'den fazla \u00e7ekim y\u00f6ntemi ile karlar\u0131n\u0131za kolay ve esnek eri\u015fim sa\u011flan\u0131r.<\/li> <\/ul> <p>Bu \u00f6zellikler, biyoteknoloji yat\u0131r\u0131mlar\u0131na karma\u015f\u0131kl\u0131k veya y\u00fcksek ba\u015flang\u0131\u00e7 maliyetleri olmadan ad\u0131m atmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option'u \u00f6zellikle uygun k\u0131lar.<\/p> <h2>\ud83c\udf0d Enliven Therapeutics 2025'te: Hassas Onkolojide \u00d6nc\u00fc<\/h2> <p>Enliven Therapeutics, kinaz inhibit\u00f6r\u00fc geli\u015ftirmeye odaklanan hassas onkolojinin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin lider aday\u0131 ELVN-001, di\u011fer tedavi se\u00e7eneklerini t\u00fcketmi\u015f ge\u00e7 evre kronik miyeloid l\u00f6semi hastalar\u0131nda etkileyici <strong>%47 maj\u00f6r molek\u00fcler yan\u0131t oranlar\u0131<\/strong> g\u00f6sterdi (<a href=\"https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-001-in-cml-at-eha-2025-congress-302481050.html\">Klinik Deneme Sonu\u00e7lar\u0131<\/a>).<\/p> <p>Enliven'i \u00f6zellikle ilgin\u00e7 k\u0131lan, tedaviye diren\u00e7li hastalara stratejik odaklanmas\u0131d\u0131r\u2014Novartis'in Scemblix gibi yeni tedavilere yan\u0131t vermeyen hastalar. Bu yakla\u015f\u0131m, y\u00fcksek ihtiya\u00e7 duyulan bir pop\u00fclasyonu hedefler ve ba\u015far\u0131l\u0131 olursa premium fiyatland\u0131rma sa\u011flayabilir.<\/p> <p>\u015eirketin merkezi Boulder, Colorado'da bulunmakta olup, yakla\u015f\u0131k 65 \u00e7al\u0131\u015fan\u0131 boru hatt\u0131n\u0131 ilerletmeye adam\u0131\u015ft\u0131r. \u0130\u015f modeli, mevcut tedavilere k\u0131yasla daha iyi g\u00fcvenlik profilleri ve hasta sonu\u00e7lar\u0131 sunan y\u00fcksek se\u00e7icilikte k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rleri geli\u015ftirmeye odaklan\u0131r.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Olumlu klinik verilerin ard\u0131ndan Enliven'in ba\u015far\u0131l\u0131 200 milyon $ sermaye art\u0131r\u0131m\u0131, sadece finansman sa\u011flamakla kalmad\u0131\u2014bu y\u0131l klinik a\u015famadaki bir CML tedavi program\u0131na yap\u0131lan en b\u00fcy\u00fck tek yat\u0131r\u0131mlardan biri olarak, tedavi direncine kar\u015f\u0131 yakla\u015f\u0131mlar\u0131na g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni i\u015faret etti.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Enliven Therapeutics Hisse Analizi: Mevcut Durum ve Gelecek Potansiyeli<\/h2>\n<p><strong>31 A\u011fustos 2025 itibar\u0131yla, Enliven Therapeutics (ELVN) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na 20,68 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>. Hisse senedi 2025 boyunca \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve 52 haftal\u0131k aral\u0131kta 13,30 $ ile 30,03 $ aras\u0131nda i\u015flem g\u00f6rerek yat\u0131r\u0131mc\u0131lar i\u00e7in hem \u00f6nemli risk hem de f\u0131rsat sundu.<\/p>\n<p>Takviminize not edin: <strong>12 Kas\u0131m 2025<\/strong>, ELVN yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 bu tarih, ge\u00e7mi\u015fte b\u00fcy\u00fck fiyat hareketlerini tetikleyebilir.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>\u00d6nemli olaylar etraf\u0131ndaki son performansa bakmak de\u011ferli i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p>\n<p><strong>13 A\u011fustos 2025<\/strong> &#8211; 2. \u00c7eyrek Kazan\u00e7 Raporu: ELVN, piyasa beklentilerinin \u00fczerinde, EPS -0,49 $ ile -0,53 $ olan konsens\u00fcs tahminini a\u015ft\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/ELVN\/earnings\/\">MarketBeat Kazan\u00e7 Verileri<\/a>). Bu olumlu s\u00fcrpriz, \u015firketin giderleri y\u00f6netme ve klinik programlar\u0131 ilerletme yetene\u011fini g\u00f6sterdi.<\/p>\n<p>Hissenin bu habere tepkisi \u00f6zellikle dikkat \u00e7ekiciydi\u2014bir\u00e7ok biyoteknoloji \u015firketi kazan\u00e7 g\u00fcnlerinde dramatik dalgalanmalar ya\u015farken, ELVN nispeten istikrar g\u00f6sterdi; bu da uzun vadeli geli\u015fim s\u00fcrecini anlayan olgun bir yat\u0131r\u0131mc\u0131 taban\u0131n\u0131 i\u015faret ediyor.<\/p>\n<h3>Alt\u0131 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h3>\n<p>ELVN, son alt\u0131 ayda zorlu ama umut verici bir yol izledi:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>\u00d6nemli Olaylar<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Trend<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>Erken klinik veri iyimserli\u011fi<\/td>\n<td>25-28 $<\/td>\n<td>\u2197\ufe0f Yukar\u0131 y\u00f6nl\u00fc momentum<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc bask\u0131s\u0131<\/td>\n<td>18-22 $<\/td>\n<td>\u2198\ufe0f Sekt\u00f6r genelinde d\u00fczeltme<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>Konferans sunumu haz\u0131rl\u0131klar\u0131<\/td>\n<td>20-24 $<\/td>\n<td>\u27a1\ufe0f Konsolidasyon<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>EHA Kongresi veri a\u00e7\u0131klamas\u0131<\/td>\n<td>22-27 $<\/td>\n<td>\u2197\ufe0f G\u00fc\u00e7l\u00fc olumlu tepki<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>Konferans sonras\u0131 kar realizasyonu<\/td>\n<td>19-23 $<\/td>\n<td>\u2198\ufe0f Sa\u011fl\u0131kl\u0131 geri \u00e7ekilme<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>2. \u00e7eyrek kazan\u00e7lar\u0131 ve kilitlenme s\u00fcresi biti\u015fi<\/td>\n<td>20-21 $<\/td>\n<td>\u27a1\ufe0f Olaylar aras\u0131nda istikrar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Avrupa Hematoloji Derne\u011fi kongresinde ELVN-001 verilerinin ard\u0131ndan %11 hisse art\u0131\u015f\u0131<\/strong> (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Oncology Pipeline Raporu<\/a>), klinik d\u00f6n\u00fcm noktalar\u0131n\u0131n bu sekt\u00f6rde de\u011ferlemeyi nas\u0131l etkiledi\u011fini g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, yat\u0131r\u0131mc\u0131lar\u0131n bekleyebilece\u011fi \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi: 25-30 $<\/strong> &#8211; Devam eden denemelerden gelen olumlu veriler, ELVN&#8217;yi son i\u015flem aral\u0131\u011f\u0131n\u0131n \u00fcst s\u0131n\u0131r\u0131na do\u011fru itebilir. Kas\u0131m kazan\u00e7lar\u0131 y\u0131l sonu ivmesini belirlemede kritik olacak.<\/p>\n<p><strong>2026 Tahmini: 35-45 $<\/strong> &#8211; Faz 2 denemeleri ba\u015far\u0131l\u0131 ba\u015flarsa ve d\u00fczenleyici yollar temizlenirse, ELVN klinik riskin azalmas\u0131yla \u00f6nemli bir yeniden de\u011ferleme g\u00f6rebilir.<\/p>\n<p><strong>2028 Projeksiyonu: 50-70 $<\/strong> &#8211; Potansiyel d\u00fczenleyici ba\u015fvurular ve ortakl\u0131k g\u00f6r\u00fc\u015fmeleri, de\u011ferlemeyi analist fiyat hedefleri olan 50 $+ aral\u0131\u011f\u0131na ta\u015f\u0131yabilir.<\/p>\n<p><strong>2030 Vizyonu: 80-100 $+<\/strong> &#8211; Ba\u015far\u0131l\u0131 ticarile\u015fme ve pazar penetrasyonu, ELVN&#8217;yi milyarlarca dolarl\u0131k bir \u015firket haline getirebilir; ancak bu tamamen klinik ba\u015far\u0131 ve d\u00fczenleyici onaya ba\u011fl\u0131d\u0131r.<\/p>\n<p><strong>Karar: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong> &#8211; 3-5 y\u0131ll\u0131k bir perspektifle. Ortalama 41,20 $ fiyat hedefi olan analist konsens\u00fcs\u00fc (<a href=\"https:\/\/stockanalysis.com\/stocks\/elvn\/forecast\/\">Stock Analysis<\/a>) mevcut seviyelerden %100&#8217;\u00fcn \u00fczerinde potansiyel y\u00fckseli\u015f anlam\u0131na geliyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong> &#8211; Biyoteknoloji hisselerinin yakla\u015f\u0131k %60&#8217;\u0131 olumsuz deneme sonu\u00e7lar\u0131nda %50&#8217;den fazla de\u011fer kayb\u0131 ya\u015far. ELVN&#8217;nin t\u00fcm de\u011ferlemesi ELVN-001&#8217;in ba\u015far\u0131s\u0131na ba\u011fl\u0131d\u0131r.<\/li>\n<li><strong>D\u00fczenleyici Gecikmeler<\/strong> &#8211; FDA inceleme s\u00fcre\u00e7leri beklenmedik \u015fekilde 6-12 ay uzayabilir, potansiyel kazan\u00e7lar\u0131 dondurur ve belirsizlik yarat\u0131r.<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong> &#8211; Yak\u0131n zamanda 200 milyon $ sermaye art\u0131r\u0131m\u0131 yap\u0131lmas\u0131na ra\u011fmen (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Sermaye Art\u0131r\u0131m\u0131 Detaylar\u0131<\/a>), \u015firketin -52,7 milyon $ negatif nakit ak\u0131\u015f\u0131 dikkatle izlenmelidir.<\/li>\n<li><strong>Y\u00fcksek Volatilite<\/strong> &#8211; G\u00fcnl\u00fck ortalama %4,37 dalgalanma ve %95 kurumsal sahiplik ile b\u00fcy\u00fck i\u015flemler hisse fiyat\u0131n\u0131 dramatik \u015fekilde etkileyebilir.<\/li>\n<\/ul>\n<h3>2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>\u00c7\u0131\u011f\u0131r A\u00e7an Klinik Veriler<\/strong> &#8211; ELVN-001, yo\u011fun tedavi g\u00f6rm\u00fc\u015f CML hastalar\u0131nda %47 MMR oranlar\u0131 g\u00f6stererek, Scemblix gibi yerle\u015fik tedavilere kar\u015f\u0131 rekabet\u00e7i konumda.<\/li>\n<li><strong>Ba\u015far\u0131l\u0131 Fonlama<\/strong> &#8211; 200 milyon $ sermaye art\u0131r\u0131m\u0131, 2029&#8217;a kadar finansal destek sa\u011flayarak k\u0131sa vadeli seyrelme endi\u015felerini azalt\u0131yor.<\/li>\n<li><strong>Analist G\u00fcveni<\/strong> &#8211; T\u00fcm 5 analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; notunu koruyor ve fiyat hedefleri 52 $&#8217;a kadar \u00e7\u0131k\u0131yor.<\/li>\n<li><strong>Pazar \u0130htiyac\u0131<\/strong> &#8211; CML, tedaviye diren\u00e7li hastalarda \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7lar\u0131 olan 7 milyar $+ b\u00fcy\u00fckl\u00fc\u011f\u00fcnde bir pazar temsil ediyor.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 ELVN gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n. Potansiyel \u00f6d\u00fcller b\u00fcy\u00fck, ancak riskler de \u00f6yle.<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong> &#8211; Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine, giri\u015f fiyat\u0131n\u0131z\u0131 ortalamak i\u00e7in birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck miktarlarda al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li>\n<li><strong>12 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong> &#8211; 3. \u00e7eyrek kazan\u00e7lar\u0131 i\u00e7in takviminize not edin ve bu olay etraf\u0131nda olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun.<\/li>\n<li><strong>Esprili t\u00fcccar bilgeli\u011fi<\/strong>: &#8220;Biyoteknolojiye yat\u0131r\u0131m yapmak lise fl\u00f6rt\u00fc gibidir\u2014%90 drama, %10 ger\u00e7ek ilerleme, ama o %10 i\u015fe yarad\u0131\u011f\u0131nda hayat de\u011fi\u015ftirebilir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri i\u00e7in rekabet\u00e7i \u00fccretler sunan bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile ba\u015flaman\u0131z i\u00e7in yeterlidir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ELVN&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>\u015eirket ad\u0131n\u0131 de\u011fil, tam borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve varsa komisyon maliyetlerini anlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Enliven Therapeutics gibi \u015firketlerle yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, piyasaya giri\u015fin daha eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Bu inan\u0131lmaz d\u00fc\u015f\u00fck giri\u015f engeli, yat\u0131r\u0131mc\u0131lar\u0131n stratejileri test etmelerine ve \u00f6nemli finansal taahh\u00fct olmadan deneyim kazanmalar\u0131na olanak tan\u0131r.<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama S\u00fcreci<\/strong> &#8211; Tek bir kimlik belgesi kullan\u0131larak 1 dakikal\u0131k KYC (M\u00fc\u015fterini Tan\u0131) s\u00fcreci sayesinde, kaydolduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li>\n<li><strong>Geni\u015f \u00c7ekim Se\u00e7enekleri<\/strong> &#8211; Kripto paralar, e-c\u00fczdanlar ve geleneksel banka se\u00e7enekleri dahil 100&#8217;den fazla \u00e7ekim y\u00f6ntemi ile karlar\u0131n\u0131za kolay ve esnek eri\u015fim sa\u011flan\u0131r.<\/li>\n<\/ul>\n<p>Bu \u00f6zellikler, biyoteknoloji yat\u0131r\u0131mlar\u0131na karma\u015f\u0131kl\u0131k veya y\u00fcksek ba\u015flang\u0131\u00e7 maliyetleri olmadan ad\u0131m atmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option&#8217;u \u00f6zellikle uygun k\u0131lar.<\/p>\n<h2>\ud83c\udf0d Enliven Therapeutics 2025&#8217;te: Hassas Onkolojide \u00d6nc\u00fc<\/h2>\n<p>Enliven Therapeutics, kinaz inhibit\u00f6r\u00fc geli\u015ftirmeye odaklanan hassas onkolojinin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin lider aday\u0131 ELVN-001, di\u011fer tedavi se\u00e7eneklerini t\u00fcketmi\u015f ge\u00e7 evre kronik miyeloid l\u00f6semi hastalar\u0131nda etkileyici <strong>%47 maj\u00f6r molek\u00fcler yan\u0131t oranlar\u0131<\/strong> g\u00f6sterdi (<a href=\"https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-001-in-cml-at-eha-2025-congress-302481050.html\">Klinik Deneme Sonu\u00e7lar\u0131<\/a>).<\/p>\n<p>Enliven&#8217;i \u00f6zellikle ilgin\u00e7 k\u0131lan, tedaviye diren\u00e7li hastalara stratejik odaklanmas\u0131d\u0131r\u2014Novartis&#8217;in Scemblix gibi yeni tedavilere yan\u0131t vermeyen hastalar. Bu yakla\u015f\u0131m, y\u00fcksek ihtiya\u00e7 duyulan bir pop\u00fclasyonu hedefler ve ba\u015far\u0131l\u0131 olursa premium fiyatland\u0131rma sa\u011flayabilir.<\/p>\n<p>\u015eirketin merkezi Boulder, Colorado&#8217;da bulunmakta olup, yakla\u015f\u0131k 65 \u00e7al\u0131\u015fan\u0131 boru hatt\u0131n\u0131 ilerletmeye adam\u0131\u015ft\u0131r. \u0130\u015f modeli, mevcut tedavilere k\u0131yasla daha iyi g\u00fcvenlik profilleri ve hasta sonu\u00e7lar\u0131 sunan y\u00fcksek se\u00e7icilikte k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rleri geli\u015ftirmeye odaklan\u0131r.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Olumlu klinik verilerin ard\u0131ndan Enliven&#8217;in ba\u015far\u0131l\u0131 200 milyon $ sermaye art\u0131r\u0131m\u0131, sadece finansman sa\u011flamakla kalmad\u0131\u2014bu y\u0131l klinik a\u015famadaki bir CML tedavi program\u0131na yap\u0131lan en b\u00fcy\u00fck tek yat\u0131r\u0131mlardan biri olarak, tedavi direncine kar\u015f\u0131 yakla\u015f\u0131mlar\u0131na g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni i\u015faret etti.<\/p>\n"},"faq":[{"question":"Enliven Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, ELVN sembol\u00fc ile arama yap\u0131n, limit emri verin ve i\u015flemi onaylay\u0131n."},{"question":"ELVN hisselerinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin 2025 y\u0131l sonu fiyat hedefi 25-30 $ aral\u0131\u011f\u0131ndad\u0131r."},{"question":"Enliven Therapeutics'in klinik \u00e7al\u0131\u015fmalar\u0131 ne durumda?","answer":"ELVN-001, ge\u00e7 evre kronik miyeloid l\u00f6semi hastalar\u0131nda %47 maj\u00f6r molek\u00fcler yan\u0131t oran\u0131 g\u00f6stermi\u015ftir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, d\u00fczenleyici gecikmeler, nakit yakma ve y\u00fcksek volatilite \u00f6nemli risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyesi nedir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, ortalama maliyetle al\u0131m yap\u0131n ve \u00f6nemli tarihleri takip edin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Enliven Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, ELVN sembol\u00fc ile arama yap\u0131n, limit emri verin ve i\u015flemi onaylay\u0131n."},{"question":"ELVN hisselerinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin 2025 y\u0131l sonu fiyat hedefi 25-30 $ aral\u0131\u011f\u0131ndad\u0131r."},{"question":"Enliven Therapeutics'in klinik \u00e7al\u0131\u015fmalar\u0131 ne durumda?","answer":"ELVN-001, ge\u00e7 evre kronik miyeloid l\u00f6semi hastalar\u0131nda %47 maj\u00f6r molek\u00fcler yan\u0131t oran\u0131 g\u00f6stermi\u015ftir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, d\u00fczenleyici gecikmeler, nakit yakma ve y\u00fcksek volatilite \u00f6nemli risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyesi nedir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, ortalama maliyetle al\u0131m yap\u0131n ve \u00f6nemli tarihleri takip edin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-31T11:01:00+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-31T11:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\",\"name\":\"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"datePublished\":\"2025-08-31T11:01:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-31T11:01:00+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-31T11:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","name":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","datePublished":"2025-08-31T11:01:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Enliven Therapeutics, Inc. (ELVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enliven Therapeutics, Inc. (ELVN) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":363841,"slug":"how-to-buy-enliven-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":363837,"slug":"how-to-buy-enliven-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Enliven Therapeutics, Inc. (ELVN) - Investimento em a\u00e7\u00f5es da Enliven Therapeutics, Inc. (ELVN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/363833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=363833"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/363833\/revisions"}],"predecessor-version":[{"id":363836,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/363833\/revisions\/363836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334036"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=363833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=363833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=363833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}